flunixin

11/01/2018 - "To study the influence of pain on the pharmacokinetics and anti-inflammatory actions of transdermal flunixin administered at dehorning. "
11/01/2018 - "Pain alters the pharmacokinetics and anti-inflammatory effects of transdermally administered flunixin."
11/01/2018 - "Maximum plasma concentrations of flunixin were 0.95 and 1.16 μg mL-1 in PAIN and NO PAIN, respectively (p = 0.089). "
11/01/2018 - "Bioavailability of transdermal flunixin was 30% and 37% in PAIN and NO PAIN, respectively (p = 0.097). "
11/01/2018 - "Plasma half-life of flunixin was significantly longer in PAIN (10.09 hours) than NO PAIN (7.16 hours) (p = 0.0202). "

03/01/2023 - "The results of this in silico study indicated that the magnitude of change in alpha and beta needed to generate violative residues exceeds that likely to occur due to disease or inflammation when flunixin is used in accordance with the approved product label."
03/01/2023 - "Using simulations to explore the potential effect of disease and inflammation on the frequency of violative flunixin residues in cattle."
06/01/1996 - "However, in animals with unilateral inflammation, flunixin reduced spinal reflexes evoked both by noxious pinch stimuli (that activate peripheral nociceptors; ID50 4 mg kg-1, i.v.) and by electrical stimuli (that bypass nociceptor endings; ID50 6.5- 11 mg kg-1, i.v.), indicating that it has a central site of action at doses comparable to those used clinically. "
10/01/2017 - "The flunixin transdermal formulation was effective in reducing PGE2 concentrations in bovine exudate following an induced inflammation. "
11/01/1984 - "Flunixin inhibits prostaglandin E2 production in equine inflammation."

01/01/2015 - "At 36 hours after flunixin administration (milk withdrawal time), 8 cows with mastitis had 5-hydroxy flunixin concentrations higher than the tolerance limit (ie, residues). "
01/01/2015 - "Comparison of pharmacokinetics and milk elimination of flunixin in healthy cows and cows with mastitis."
10/01/2003 - "The efficacy of meloxicam in the treatment of sows with mastitis-metritis-agalactia syndrome was investigated in comparison with flunixin. "
08/01/2002 - "The efficacy of flunixin alone and together with enrofloxacin in treatment of experimental Escherichia coli mastitis was compared using six cows. "
09/01/1986 - "Flunixin fails to enhance cloxacillin in treatment of experimental staphylococcal mastitis in mice."

12/01/2014 - "Giving a single injection of flunixin had no brand-specific effects on sensitivity, surface temperature, or healing but improved weight gain in the days after branding in all treated groups (flunixin×brand×day, P<0.001). "
02/01/2003 - "Flunixin reduced wound inflammation and improved weight gain, but had no effect on nociceptive thresholds. "

06/01/2007 - "Meloxicam- or flunixin-treated horses had improved postoperative pain scores and clinical variables, compared with SS-treated horses. "
05/01/1977 - "Efficacy and tolerance of Flunixin (SCH 14714) in the treatment of postoperative pain, with observations on the methodology of postoperative pain studies."
09/01/1996 - "A comparison of ketorolac with flunixin, butorphanol, and oxymorphone in controlling postoperative pain in dogs."
01/01/2003 - "These findings suggest that potent nonsteroidal anti-inflammatory agents, such as flunixin, may be useful alternatives to opioid-based agents for the control of acute postoperative pain associated with a minor surgical procedure and highlight the importance of assessing the risk-benefit ratio when selecting analgesics and dosing regimens."